GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.46 USD | -0.12% |
|
+0.40% | -19.20% |
| May. 07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
| May. 02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
ETFs positioned on Gilead Sciences, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.20% | 0 M€ | +4.68% | - | |
| 0.20% | 0 M€ | +0.87% | - | |
| 0.20% | 0 M€ | +4.68% | - | |
| 0.20% | 0 M€ | +6.07% | - | |
| 0.19% | 14 M€ | +16.19% | - | |
| 0.18% | 0 M€ | +11.74% | - | |
| 0.18% | 284 M€ | -.--% | ||
| 0.17% | 1,166 M€ | +0.26% | - | |
| 0.17% | 607 M€ | +0.05% | - | |
| 0.17% | 1 M€ | +3.03% | - | |
| 0.17% | 206 M€ | -.--% | ||
| 0.17% | 23 M€ | -.--% | - | |
| 0.17% | 786 M€ | -.--% | ||
| 0.17% | 0 M€ | +17.39% | ||
| 0.15% | 0 M€ | +8.16% | - | |
| 0.15% | 0 M€ | 0.00% | - | |
| 0.14% | 0 M€ | +6.11% | - | |
| 0.12% | 0 M€ | +7.51% | - | |
| 0.12% | 0 M€ | +3.30% | - | |
| 0.11% | 2 M€ | +3.16% | - | |
| 0.10% | 0 M€ | -1.36% | - | |
| 0.09% | 0 M€ | +11.33% | - | |
| 0.09% | 0 M€ | +5.64% | - | |
| 0.09% | 0 M€ | +4.96% | - | |
| 0.09% | 0 M€ | +0.34% | - |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
01:00pm
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.46
USD
Average target price
82.93
USD
Spread / Average Target
+26.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.20% | 81.63B | |
| +33.43% | 700B | |
| +26.43% | 569B | |
| -5.12% | 358B | |
| +19.59% | 330B | |
| +4.89% | 287B | |
| +14.32% | 236B | |
| +5.79% | 202B | |
| -9.49% | 197B | |
| +4.26% | 161B |
- Stock Market
- Equities
- GILD Stock
- Funds and ETFs Gilead Sciences, Inc.